ライフサイエンスコーパス: trial

1 (9 smaller early-phase and 2 larger outcome trials).

2 trials), or postmenopausal women with CKD (4 trials).

3 age, 68 years; 16% women), 333 completed the trial.

4 diac cause that had been included in the TTM-trial.

5 Site and Systemic Implementation of Angiox) trial.

6 r Ticagrelor and Patient Outcomes (SOCRATES) trial.

7 ionale for a confirmatory phase III clinical trial.

8 in 4 samples from 2 persons in the clinical trial.

9 lternative medications were included in this trial.

10 ive, randomized, multicenter, single-blinded trial.

11 two subjects that were part of the phase II trial.

12 No deaths occurred in this trial.

13 ors were requested from the leaders of the 6 trials.

14 associations that shared features with other trials.

15 in activity have already moved into clinical trials.

16 and as a surrogate biomarker in intervention trials.

17 nt and less participation of men in clinical trials.

18 itant chemotherapy with the inclusion of new trials.

19 ical practice and for the design of clinical trials.

20 ncluded in the standard repair group of both trials.

21 th 3 compounds failing in phase III clinical trials.

22 y for mild cognitive impairment and dementia trials.

23 -month prospective, randomized, FAME A and B trials.

24 ently already used in phase 2, 3, and even 4 trials.

25 o date, no vaccines have made it to clinical trials.

26 ations for stratification of future clinical trials.

27 n extracted data from fair- and good-quality trials.

28 , with robust effects at the level of single trials.

29 een 47% and 56% less pollen by the end of 10 trials.

30 g in oncology have been small, single-center trials.

31 sening of accrual for neoadjuvant/metastatic trials.

32 H) is hampered by lack of pediatric clinical trials.

33 loid PET assessment in clinical practice and trials.

34 ral other compounds are in advanced clinical trials.

35 survival as well as overall survival in both trials.

36 r second neoplasias were observed in in both trials.

37 rospective cohort studies and interventional trials.

38 ophageal junction adenocarcinoma, Intergroup Trial 0116 (Phase III trial of postoperative adjuvant ra

39 al trials: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).

40 Of 127 patients in the AIM Dysplasia trial, 119 received RFA and met inclusion criteria.

41 One participant withdrew from the trial 240 days after enrolment and 12 died during follow

42 Single site randomized control trial, 3 groupsx4 time points mixed factorial design con

43 le-blind, placebo-controlled, parallel-group trial, 401 participants aged 6 to 11 years were randomiz

44 weight regain.In this randomized controlled trial, 61 healthy overweight or obese participants follo

45 r search; of 1764 patients included in these trials, 871 were allocated to endovascular thrombectomy

46 efficacy and safety results from 13 polypill trials (9059 participants) done in 32 countries.

47 le-blind, placebo-controlled, parallel-group trial, 93 EoE patients between the ages of 11 and 40 yea

48 o achieve the primary efficacy end point: in trial A, 188 of 254 (74.0%) vs 21 of 254 (8.3%; P < .001

49 roduction to Enhance Performance in Dialysis trial, a 6-month randomized, multicenter trial to test w

50 on after Percutaneous Coronary Intervention) trial, a clinical trial in which 2,604 patients with chr

51 hough some of these vaccines are in clinical trials, a lack of knowledge about the molecular basis th

52 erapies have been tested in phase I clinical trials, a quarter of which have reached phase II/III.

53 sequential patient samples from the clinical trial and correlated these with clinical response.

54 FR was measured every 2 months in the ESCAPE Trial and every 6 months in the 4C Study.

55 carried out separately for each trial (mesh trial and graft trial) some women in the standard repair

56 agonist, reduced tobacco smoking in a 4-week trial and in animal models has been shown to reduce cort

57 no financial coverage for ASCT in a clinical trial and instead received melphalan at 200 mg/m(2) intr

58 significantly differ between the ML-DS 2006 trial and the historical control arm.

59 randomized controlled design by pre-approval trials and 2) the treatment-by-biomarker interaction.

60 nsistently reported in greater than half the trials and greater than half the reviews.

61 therapies were efficient only in preclinical trials and have suggested the existence of resistance me

62 , objective assessments of itch for clinical trials and practice.

63 s at our institution before inclusion in the trial (and thus just before chemotherapy).

64 CONSORT (Consolidated Standards of Reporting Trials) and SPIRIT (Standard Protocol Items: Recommendat

65 spective reports and one randomized clinical trial, and five retrospective studies were included in v

66 may be difficult and, typically, based on a trial-and-error approach.

67 Randomized controlled trials are required to confirm these results.

68 t drugs currently being assessed in clinical trials are targeting the downstream sequelae of this pri

69 Further data from randomized controlled trials are urgently needed because lepirudin was recalle

70 city was not significantly different between trial arms.

71 This trial assessed the hypothesis that platelets collected f

72 We report results of the first phase 3 trial assessing long-acting intramuscular pasireotide in

73 Results We identified 51 trials assessing 14 drugs across 15 conditions.

74 Double-blinded, placebo-controlled trial at 9 academic medical centers in the United States

75 rtions of 65.7% (95% CI, 59.4%-72.1%) and in trial B, 192 of 255 (75.3%) vs 25 of 260 (9.6%; P < .001

76 that differed only in the number of rewarded trials between goal reversals.

77 son Cancer Center who were eligible for this trial but declined to participate or had no financial co

78 rved some improvement in accrual to adjuvant trials but worsening of accrual for neoadjuvant/metastat

79 RSV entry blockers are in clinical trials, but escape mutations challenge their potential.

80 king the transition into early-phase patient trials, but the lack of validated biomarkers of disease

81 el-design, double-blind, randomized clinical trial, called Resveratrol to Improve Outcomes in Older P

82 ID), Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Database of Systematic Review

83 and pharmacodynamic substudy from 4 phase 2 trials, circulating PCSK9 levels were measured at baseli

84 ooperative Huntington Observational Research Trial (COHORT).

85 The present multicenter trial compared 12 weeks of supervised interventions of H

86 ISE-ETP) study, a 34-site cluster-randomized trial, compared NAVIGATE, a coordinated specialty care p

87 randomized, double-blind, placebo-controlled trial comparing 150 million bone marrow mononuclear cell

88 hibition [PLATFORM]: NCT00385138; A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therap

89 BENEFIT was a randomized clinical trial comparing early versus delayed interferon beta-1b

90 ectronic databases for randomized controlled trials comparing AL to non-ACTs that reported gametocyte

91 contribute to venous thrombosis has prompted trials comparing anticoagulants with aspirin for seconda

92 The ALLOZITHRO parallel-group trial conducted in 19 French academic transplant centers

93 ndomized, double-blinded, placebo-controlled trial conducted in malaria-endemic Uganda, comparing hyd

94 Women's Health Initiative (WHI), a series of trials conducted in the United States, during the period

95 r OS rate, long-term follow-up of the FOLL05 trial confirms the favorable outcome of patients with ad

96 identifies HTEs, using a random half of the trial data (the training set).

97 ss these estimates in light of more clinical trial data and to understand the effect on an individual

98 No correlation was found in pooled RVO trial data.

99 e same platform structure and makes clinical trial design decisions more explicit.

100 ay for patient selection may inform clinical trial design for immunotherapy in pancreatic cancer.

101 Although clinical trial design is challenging, due in part to a lack of ro

102 artery disease cell therapy investigational trial design may be informed by new anatomic and perfusi

103 ortance to routine patient care and clinical trial design.

104 n of patient and caregiver perspectives into trial design.

105 Trial designs for new transplant immunosuppression must

106 improving perioperative outcomes in research trials, effective methods of population-based implementa

107 e III clinical trials only the RV144 vaccine trial elicited significant protection against HIV-1 acqu

108 The broadening of clinical trial eligibility criteria can be considered to better r

109 Between Nov 4, 2010, and Dec 7, 2015, the trial enrolled 399 patients and was terminated after a p

110 ese randomised, phase 2, open-label clinical trials enrolled individuals from 15 countries who were c

111 From a group of 79 patients included in a trial evaluating the role of pretreatment circulating tu

112 to identify high-risk patients, and clinical trials evaluating novel therapies should be focused on t

113 Randomized trials evaluating treatment levels significantly above 9

114 This randomized controlled trial examined the efficacy of a novel gaze-contingent m

115 on recently published randomized controlled trials exploring the efficacy of oral tolerance inductio

116 cal samples collected during the NCT00632476 trial followed by independent validation of selected cor

117 neurodegenerative disorders, with a phase II trial for RP under way.

118 Compound 25 was advanced to first-in-man trials for the treatment of psychiatric conditions.

119 emethylase 1 inhibitor currently in clinical trials for the treatment of small cell lung carcinoma, w

120 imals, and there are no large-scale clinical trials for therapies against MERS-CoV.

121 This prospective, randomized trial found that treat and extend dosing of ranibizumab

122 FAME 2 trial (Fractional Flow Reserve Versus Angiography for Mu

123 inical outcome in patients from FAME 1 and 2 trials (Fractional Flow Reserve or Angiography for Multi

124 ol Items: Recommendations for Interventional Trials) guideline authors (n = 16), pharmaceutical indus

125 This trial has been completed and the final results are repor

126 some inhibitor bortezomib, but no systematic trial has been undertaken to support its use in ABMR.

127 een protective efficacy in the RV144 vaccine trial have important societal implications.

128 Randomized trials have demonstrated increased morbidity with libera

129 However, clinical trials have produced inconsistent results.

130 Virology Research Clinic) and HIV prevention trials (HIV Prevention Trials Network 039 and Partners i

131 ve been extensively demonstrated in clinical trials; however, its performance in routine health care

132 ver-blind, randomised controlled superiority trial (IMPACT) at 15 National Health Service child and a

133 We did a cluster-randomised, controlled trial in 12 hospitals in Guangxi, China.

134 We did this randomised controlled trial in 18 SSSs in England.

135 randomized, double-blind, placebo-controlled trial in 27 centers across North America to determine th

136 PREDIMED (PREvencion con DIeta MEDiterranea) trial in 983 participants [230 cases and a random subcoh

137 ve, randomised, open-label, blinded-endpoint trial in adult participants with ischaemic stroke or tra

138 The START trial was a randomised controlled trial in ART-naive HIV-positive patients with CD4 cell c

139 community-based three-arm cluster randomised trial in healthy children aged 1 month to 5 years that r

140 Randomized 2 x 2 factorial clinical trial in neonates (>/=36 weeks' gestation) with hypoxic-

141 n this multicentre, double-blind, randomised trial in seven Danish university clinics, we recruited c

142 ous Coronary Intervention) trial, a clinical trial in which 2,604 patients with chronic angina and in

143 SWIFT-C) is an open-label, 2-cohort clinical trial in which the first cohort assessed for the safety

144 double-blind, randomised, placebo-controlled trials in adults with chronic non-cancer pain and opioid

145 ensing, we review the outcomes from clinical trials in children with persistent AA receiving omalizum

146 elopment Conference on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease.

147 evelopment Projects on Criteria for Clinical Trials in Chronic GVHD standardized the terminology arou

148 endpoints that are traditional for clinical trials in Crohn's disease, and identify factors that pre

149 In 2 randomized trials in Guinea-Bissau of early BCG-Denmark (Statens Se

150 atients with enteric fever randomized into 4 trials in Kathmandu, Nepal, were pooled.

151 clinical trials of the Alliance for Clinical Trials in Oncology.

152 ensed drug, should now be tested in clinical trials in patients.

153 for refining inclusion criteria of clinical trials in the settings of T1D.

154 ng NASH and underscore the need for clinical trials in this area.

155 Randomized clinical trials in which self-guided iCBT was compared with a con

156 randomized, double-blind, placebo-controlled trial included patients with schizophrenia, schizoaffect

157 e (NHP) studies as well as the RV144 vaccine trial indicate that non-neutralizing antibodies can cont

158 tosis in a randomized, double-blind clinical trial involving 131 participants.

159 single-center, double-blind, noninferiority trial involving adults with unipolar depression, we rand

160 In this preliminary report of a trial involving patients undergoing PCI, there was no si

161 iours, possibly due to the limited number of trials involving women's groups and context-specific eff

162 A phase 1 clinical trial is in progress to investigate the therapeutic pote

163 A randomized trial is needed.

164 Multicenter, placebo-controlled, randomized trial (July 2013 to final follow-up October 2014) conduc

165 neural oscillatory activities at the single trial level were further calculated with the inter-trial

166 TION: Two reviewers independently abstracted trial-level data including population characteristics, i

167 s of individual neurons varied widely across trials, many cells tended to covary with the local popul

168 nalyses were carried out separately for each trial (mesh trial and graft trial) some women in the sta

169 Eighteen trials (n = 40058; range, 142-16608; mean age, 53-79 yea

170 There were 13 trials (n = 9850) that included kidney transplant recipi

171 c) and HIV prevention trials (HIV Prevention Trials Network 039 and Partners in Prevention HSV/HIV Tr

172 id a phase 4, open-label, cluster randomised trial of 22 communities in rural KwaZulu-Natal, South Af

173 A phase 1 trial of 45 children and young adults with relapsed or r

174 e, this is the largest randomised controlled trial of a psychological intervention for a mental healt

175 CH) study is a cluster-randomised controlled trial of an HIV test-and-treat strategy in 32 rural comm

176 We conducted the first randomized trial of behavioral weight loss for HIV-infected patient

177 tudy, which is to our knowledge, the largest trial of CIDP to date and the first to study two adminis

178 ix CAE children in a randomized double-blind trial of ethosuximide, lamotrigine, and valproate had sh

179 FOURIER was a randomized trial of evolocumab versus placebo in 27 564 patients wi

180 clinical efficacy and safety in the FOURIER trial of evolocumab, a monoclonal antibody to proprotein

181 th lymphoma who were treated in a randomised trial of front-line chemotherapy with cyclophosphamide,

182 placebo-controlled, multiple-ascending-dose trial of inclisiran administered as a subcutaneous injec

183 In a recent trial of intermittent preventive treatment in pregnancy

184 Four-group cluster randomized clinical trial of mothers of healthy term newborns who were recru

185 In a phase 2B randomized trial of patients with moderate to severe DG, relamoreli

186 ocarcinoma, Intergroup Trial 0116 (Phase III trial of postoperative adjuvant radiochemotherapy for hi

187 ed participants from a randomized controlled trial of primary prevention with statin therapy (WOSCOPS

188 compared a cohort of patients enrolled on a trial of reduced-intensity allo-HSCT with standard GVHD

189 dertook a double-blind randomised controlled trial of small-quantity lipid-based nutrient supplements

190 proach that has demonstrated safety in human trials of an rVSV/HIV-1 vaccine.

191 s a primary end point in randomized clinical trials of chemoimmunotherapy in CLL.

192 opment of clinically relevant biomarkers and trials of combination therapies.

193 son's disease, which may be used in clinical trials of disease-modifying therapies.

194 ClinicalTrials.gov for phase II to IV cancer trials of Food and Drug Administration-approved immunoth

195 patient data from 13 randomized multicenter trials of induction and maintenance regimens in first-li

196 Additional trials of medications aimed at targeting cytokine overac

197 Thus far, most trials of novel molecular imaging in oncology have been

198 Pragmatic clinical trials of terlipressin with albumin are warranted to eva

199 SEER) database and data from the 10 clinical trials of the Alliance for Clinical Trials in Oncology.

200 In this randomized trial, off-pump CABG led to lower rates of 5-year surviv

201 Median follow-up at the end of the trial on Nov 5, 2014, was 49.6 months in each treatment

202 Among the phase III clinical trials only the RV144 vaccine trial elicited significant

203 d, multicenter, phase 3, randomized clinical trial open to patients with biopsy-proven carcinoma of t

204 ican American Families randomized prevention trial or to a control condition.

205 age 3 to 5 CKD or were receiving dialysis (3 trials), or postmenopausal women with CKD (4 trials).

206 Of 3170 trial participants, 394 (12.4%) had BWF.

207 ere older and had more advanced disease than trial participants.

208 l-world patient population, improve clinical trial participation, and increase patient access to new

209 hat included kidney transplant recipients (6 trials), patients who had stage 3 to 5 CKD or were recei

210 ingle-centre, two-stage, phase 2, single-arm trial, patients (aged >/=16 years) with histologically c

211 bel, blinded-endpoint, randomised controlled trial, patients aged 70 years or younger with aphasia af

212 In this randomised, phase 3, open-label trial, patients were screened for eligibility from 52 cl

213 s In this double-blinded, placebo-controlled trial, patients with HER2-positive early breast cancer w

214 om 13 countries reviewed data from published trials performed through cooperative groups, consortia,

215 r events by 25% (P=0.037) during the initial trial phase and the risk of coronary heart disease death

216 level were further calculated with the inter-trial phase coherence (ITPC) measure for the theta and b

217 reviews, meta-analyses, randomized clinical trials, prospective comparative observational studies, a

218 The Cochrane Central Register of Controlled Trials, Prospero, Medline (1946-December week 1 2016), P

219 TWENTE participants was prespecified in the trial protocol; that of the nonenrolled participants was

220 The findings of randomised controlled trials (RCT), observational studies, and meta-analyses v

221 med a meta-analysis of randomised controlled trials (RCTs) to assess whether intensive BP lowering in

222 t 29, 2014, a randomised 2 x 2 x 3 factorial trial recruited 6- to 23-month-old children with MAM in

223 Dutch Clinical Trial Registration no: NL30551.068.09.

224 toward a face or a house that, on different trials, remained the same, changed, or disappeared durin

225 In 2 large, randomized, double-masked trials reported here, once-daily dosing of netarsudil 0.

226 onal, phase 3, double-blind, non-inferiority trial (REPROVE).

227 tress, could have contributed to the neutral trial results in RELAX.

228 To use the trial results to determine the cost-effectiveness of a P

229 e-masked, randomized noninferiority clinical trials: Rho Kinase Elevated IOP Treatment Trial 1 and 2

230 A total of 41 men were enrolled between the trial's activation on August 9, 2011, and closure on Aug

231 long observation period outside the clinical trial scenario.

232 When <10 rewarded trials separated goal switches, OFC population vectors d

233 data meta-analysis of randomised controlled trials showed that vitamin D supplementation reduces the

234 arately for each trial (mesh trial and graft trial) some women in the standard repair arm assigned to

235 Finally, as with many trials, some placebo-treated participants showed improve

236 much smaller, randomized, placebo-controlled trials specifically designed to evaluate statin therapy

237 single-blind, phase 2, randomised controlled trial (SUPEREDEN3) at four specialist early intervention

238 Randomized trials support the use of transcatheter aortic valve rep

239 tre, randomised, placebo-controlled, phase 3 trial (TACE 2) in 20 hospitals in the UK for patients wi

240 multicentre, randomised, open-label, phase 3 trial that enrolled participants at 38 participating Chi

241 recommended schema for a randomised phase 3 trial that might potentially answer this question defini

242 glish-language cohort studies and randomized trials that compared different doses of naloxone, admini

243 Clinical trials that include racial and ethnic groups need to con

244 Randomized trials that reported pain, function, or harms of systemi

245 n perhaps the strongest adjuvant in clinical trials (that is, CpG in Montanide).

246 At the 2 x 10(7) PFU dose (used in phase 3 trials), the most common local adverse events versus pla

247 A multicenter phase 2 randomized clinical trial, the Arginine Deiminase and Mesothelioma (ADAM) st

248 In both trials, the proportion of patients who discontinued trea

249 (A Clinical Trial to Demonstrate the Efficacy of Cangrelor [PCI]: NC

250 sis trial, a 6-month randomized, multicenter trial to test whether a simple, personalized walking exe

251 rformed a parallel-arm randomized controlled trial to test whether administration of an extensively h

252 A prospective trial to validate this concept is warranted.

253 mine whether to modify definitions to extend trials to a broader population.

254 and create a network of randomized clinical trials to compare outcomes after specific treatment dura

255 Two clinical trials to define novel ways of using an existing antibio

256 These findings support conducting randomized trials to explore risks and benefits of OAT resumption a

257 usion, may be appropriate subjects of future trials to improve outcomes of children requiring this su

258 We show that trial-to-trial variability in the reaction time and accu

259 tion of the experiment, and thereby discover trial-to-trial variability in the spike-field coherence

260 a multi-day fMRI study, participants encoded trial-unique associations that shared features with othe

261 e Delphi survey was sent to statisticians in trial units who completed the survey of current practice

262 of Drug Efficacy is a randomized controlled trial using a multiarm, multistage, platform design.

263 ssess HSCT in patients enrolled in the ASTIC trial using endpoints that are traditional for clinical

264 lot a cluster-randomized, multiple-crossover trial using software tools within the electronic health

265 We show that trial-to-trial variability in the reaction time and accuracy of e

266 he experiment, and thereby discover trial-to-trial variability in the spike-field coherence of a rat

267 The phase 3 ENDEAVOR trial was a head-to-head comparison of two proteasome in

268 The START trial was a randomised controlled trial in ART-naive HIV

269 Conclusion This trial was carried out on a worldwide intergroup basis, a

270 A randomized clinical trial was conducted from February 1 to August 31, 2015,

271 A prospective, international 1:1 randomized trial was conducted to evaluate in a noninferiority desi

272 This trial was done at MD Anderson Cancer Center between 1999

273 d, double-blind, parallel-group, superiority trial was done in 18 hospitals across Europe.

274 ndomised, double-blind, multicentre, phase 3 trial was done in 87 centres in 21 countries worldwide.

275 This trial was not large enough or of long enough duration to

276 primary outcome for the phase 3 stage of the trial was overall survival (defined as the time from ran

277 The trial was registered at EudraCT as #2007-006219-2.

278 The primary outcome of the trial was the rate of corneal perforation or the need fo

279 The primary purpose of this trial was to assess the effectiveness of ketamine for pr

280 The primary objective of this trial was to evaluate safety of IVT or an estradiol vagi

281 The ART (Arterial Revascularization Trial) was designed to compare survival after bilateral

282 open-label, randomised, phase 3, multicentre trial, we enrolled adult patients with CD30-positive myc

283 is ongoing, multicentre, open-label, phase 2 trial, we enrolled adults (aged >/=18 years) with histol

284 In this randomised, controlled, phase 3 trial, we recruited patients at a single tertiary cancer

285 In this randomised controlled trial, we recruited patients from 34 general practices i

286 In two identical phase 3 trials, we randomly assigned 821 and 835 patients with r

287 Overall, all 1059 patients from the Mainsail trial were included (mean [SD] age, 68.7 [7.89] years).

288 Seven trials were identified by our search; of 1764 patients i

289 In total, 17 randomized controlled trials were identified, including 18 treatment options.

290 y bioprocessing, two independent aquaculture trials were performed.

291 us performed a randomized placebo-controlled trial with atorvastatin 40 mg/day for 9 weeks in 14 SPG5

292 l Gambia.The sample comprised 670 women in a trial with serial weight data (7310 observations) that w

293 Twenty-three randomized controlled trials with 2,751 patients were included.

294 Of these, seven trials with 363 dental implants in 262 participants were

295 samples obtained from 3 independent clinical trials with drisapersen, an antisense oligonucleotide ta

296 Current trials with drugs that target BS toxicity are effective

297 nt ES estimates were 0.13 and 0.15 larger in trials with inadequate/unknown sequence generation and i

298 More recently, clinical trials with Janus kinase (JAK) inhibitors have shown tha

299 human blood serum, by the spike and recovery trials with seawater, tap water, mineral water, and alco

300 jective decision times (tSDs) were faster on trials with stronger (easier) motion, and they were well